Abstract
Objectives: Evaluating the effectiveness of 2 therapeutic schemes for chronic hepatitis C (genotype 6) which combined sofosbuvir and ribavirin, one of them also included pegylated interferon. Materials and methods: The study included 110 patients with chronic hepatitis C (genotype 6), who have undergone antiviral therapy (HTP) in Hepatology Clinic inHo Chi Minh City,Vietnamfrom November 2015 to July 2016. 24 patients were treated by Pegylated interferon alfa-2a, ribavirin and sofosbuvir for 12 weeks, 86 patients – by sofosbuvir and ribavirin for 24 weeks. Non-interferon regimen was administered primarily to patients with contraindications to the use of interferon. To monitor the effectiveness of antiviral therapy, quantification of HCV RNA in serum was performed by PCR prior to treatment, at 4th, 12th or 24th week (depending on the observation group) from the starting of treatment and at 12th, 24th week after completion of treatment. Results: All patients, who were treated with pegylated interferon, ribavirin and sofosbuvir, completed the full course of treatment and 100% of them are registered with sustained virological response at 12th and 24th week after the end of antiviral therapy (SVR-12 and SVR-24, respectively). In the group of patients, who treated with ribavirin and sofosbuvir, 97,7% of patients completed full course of treatment (SVR-12 was registered in 93% of patients, and SVR-24 – in 91,9% of patients). Of 75 patients without a history of HCC, SVR24 was registered in 74 people (98,7%), of 11 patients with HCC – in 5 patients (45,5%). SVR-24 was registered in 98% of patients with cirrhosis (F4) without HCC. Conclusion: The results can serve as a justification for the use of these schemes of antiviral therapy for special groups of patients and/or conditions when it is impossible to follow the latest recommendations, which will help to expand the access of patients to effective antiviral therapy for chronic hepatitis C.
Highlights
Устойчивый вирусологический ответ через 12 недель после окончания лечения зарегистрирован у 80 больных (93%), через 24 недели – у 79 пациентов (91,9%)
Как видно из данных рисунков 2 и 3, у больных без ГЦК в анамнезе недостаточный ответ на терапию был ассоциирован с наличием цирроза печени
EASL Recommendations on Treatment of Hepatitis C 2016
Summary
ОЦЕНКА ЭФФЕКТИВНОСТИ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКОГО ГЕПАТИТА C, ВЫЗВАННОГО ВИРУСОМ ГЕНОТИПА 6. Санкт-Петербург, Россия 3 Медицинский и фармацевтический университет, Хошимин, Вьетнам 4 Гепатологическая клиника, Хошимин, Вьетнам 5 Институт им. Резюме Цель: оценка эффективности 2 схем комбинированной терапии ХГС (генотип 6) софосбувиром и рибавирином, одна их которых также включала пегилированный интерферон. Материалы и методы: в исследование включены 110 больных ХГС (генотип 6), прошедших курс противовирусной терапии (ПВТ) в клинике гепатологии в г. Результаты: все больные, получавшие пегилированный интерферон, софосбувир и рибавирин, закончили полный курс лечения, и у 100% из них зарегистрирован устойчивый вирусологический ответ через 12 и 24 недели после окончания ПВТ (УВО-12 и УВО-24 соответственно). В группе больных, получавших софосбувир и рибавирин, полный курс лечения завершили 97,7% больных (УВО-12 зарегистрирован у 93% больных, а УВО-24 – у 91,9% пациентов). Заключение: полученные результаты могут служить обоснованием применения указанных схем ПВТ в особых
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.